A metabolic profile of routine needle biopsies identified tumor type specific metabolic signatures for breast cancer stratification: a pilot study
A metabolic profile of routine needle biopsies identified tumor type specific metabolic signatures for breast cancer stratification: a pilot study
复制标题
DOI：
10.1007/s11306-019-1610-6
复制
发表时间：
2019-11-01
期刊：
影响因子：
3.6
通讯作者：
Ishida, Takanori
中科院分区：
文献类型：
--
作者：
Harada-Shoji, Narumi;Soga, Tomoyoshi;Ishida, Takanori
代谢组学最近成为理解肿瘤相关代谢失调的一种工具。然而，这项技术在乳腺癌临床中的应用非常有限。本研究的目的是确定利用乳腺癌患者常规CNB/VAB样本进行代谢组分析的可行性，并利用代谢谱分析阐明代谢特征。方法连续20例乳腺癌筛查后行CNB/VAB，经组织学诊断为良性、DCIS和IDC。采用CE-MS进行代谢组学分析。然后用MetaboAnalyst 4.0分析和评估差异代谢物。结果测定了116种参与能量代谢的目标代谢物。主成分分析和无监督层次分析显示，“纯”IDC样本具有独特的代谢特征，而DCIS的代谢特征与良性样本相似。途径分析揭示了“纯”IDC代谢型受影响最大的途径，包括“嘧啶”、“丙氨酸、天冬氨酸和谷氨酸”和“精氨酸和脯氨酸”途径。我们的概念验证研究表明，基于ce - ms的CNB/VAB代谢组分析在常规临床环境中是可行的。本研究中受影响最大的途径可能有助于改善乳腺癌分层和精准医学。
Introduction Metabolomics has recently emerged as a tool for understanding comprehensive tumor-associated metabolic dysregulation. However, only limited application of this technology has been introduced into the clinical setting of breast cancer. Objectives The aim of this study was to determine the feasibility of metabolome analysis using routine CNB/VAB samples from breast cancer patients and to elucidate metabolic signatures using metabolic profiling. Methods After breast cancer screenings, 20 consecutive patients underwent CNB/VAB, and diagnosed with benign, DCIS and IDC by histology. Metabolome analysis was performed using CE-MS. Differential metabolites were then analyzed and evaluated with MetaboAnalyst 4.0. Results We measured 116-targeted metabolites involved in energy metabolism. Principal component analysis and unsupervised hierarchical analysis revealed a distinct metabolic signature unique to namely "pure" IDC samples, whereas that of DCIS was similar to benign samples. Pathway analysis unveiled the most affected pathways of the "pure" IDC metabotype, including "pyrimidine," "alanine, aspartate, and glutamate" and "arginine and proline" pathways. Conclusions Our proof-of-concept study demonstrated that CE-MS-based CNB/VAB metabolome analysis is feasible for implementation in routine clinical settings. The most affected pathways in this study may contribute to improved breast cancer stratification and precision medicine.